CA2216623C - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections Download PDF

Info

Publication number: CA2216623C
Authority: CA; Canada
Prior art keywords: fumagillol; intestinal infections; preparation; fumagillin; drugs
Prior art date: 1995-03-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002216623A

Other languages

English (en)

French (fr)

Other versions

CA2216623A1 (en

Inventor

Jean-Michel Molina

Francis Derouin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Assistance Publique Hopitaux de Paris APHP

Sanofi Aventis France

Original Assignee

Sanofi Synthelabo SA

Assistance Publique Hopitaux de Paris APHP

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-27

Filing date

1996-03-26

Publication date

2005-05-31

1996-03-26 Application filed by Sanofi Synthelabo SA, Assistance Publique Hopitaux de Paris APHP filed Critical Sanofi Synthelabo SA

1996-10-03 Publication of CA2216623A1 publication Critical patent/CA2216623A1/en

2005-05-31 Application granted granted Critical

2005-05-31 Publication of CA2216623C publication Critical patent/CA2216623C/en

2016-03-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 title claims abstract description 21
CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 title claims abstract description 21
239000003814 drug Substances 0.000 title claims abstract description 12
206010022678 Intestinal infections Diseases 0.000 title claims abstract description 10
150000002148 esters Chemical class 0.000 claims abstract description 15
241000243190 Microsporidia Species 0.000 claims abstract description 14
239000002253 acid Substances 0.000 claims abstract description 14
238000002360 preparation method Methods 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 7
229920006395 saturated elastomer Polymers 0.000 claims abstract description 7
NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 claims description 13
NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical group C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 claims description 13
229960000936 fumagillin Drugs 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 11
229940079593 drug Drugs 0.000 claims description 9
239000007903 gelatin capsule Substances 0.000 claims description 9
241001442406 Enterocytozoon bieneusi Species 0.000 claims description 7
244000045947 parasite Species 0.000 claims description 6
230000003111 delayed effect Effects 0.000 claims description 4
238000013270 controlled release Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
150000007513 acids Chemical class 0.000 abstract description 6
238000011282 treatment Methods 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
230000008029 eradication Effects 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000001574 biopsy Methods 0.000 description 3
230000002183 duodenal effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001493 electron microscopy Methods 0.000 description 3
206010001513 AIDS related complex Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000002141 anti-parasite Effects 0.000 description 2
239000003096 antiparasitic agent Substances 0.000 description 2
229940125687 antiparasitic agent Drugs 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
QHYKVJVPIJCRRT-UHFFFAOYSA-N deca-2,4,6,8-tetraenedioic acid Chemical class OC(=O)C=CC=CC=CC=CC(O)=O QHYKVJVPIJCRRT-UHFFFAOYSA-N 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229910002012 Aerosil® Inorganic materials 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
241001126846 Encephalitozoon hellem Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
238000009341 apiculture Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000003157 cancerolytic effect Effects 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000003108 parasitologic effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
238000009372 pisciculture Methods 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000004562 water dispersible granule Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Epoxy Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002216623A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections Expired - Lifetime CA2216623C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR95/03549		1995-03-27
FR9503549		1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr)	1995-03-27	1996-03-26	Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number	Publication Date
CA2216623A1 CA2216623A1 (en)	1996-10-03
CA2216623C true CA2216623C (en)	2005-05-31

Family

ID=9477436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002216623A Expired - Lifetime CA2216623C (en)	1995-03-27	1996-03-26	Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections

Country Status (25)

Country	Link
US (1)	US5900431A (2)
EP (1)	EP0817626B1 (2)
JP (1)	JP3260378B2 (2)
KR (1)	KR100286920B1 (2)
CN (1)	CN1072485C (2)
AP (1)	AP646A (2)
AT (1)	ATE172641T1 (2)
AU (1)	AU706161B2 (2)
CA (1)	CA2216623C (2)
CZ (1)	CZ286821B6 (2)
DE (1)	DE69600879T2 (2)
DK (1)	DK0817626T3 (2)
EA (1)	EA000150B1 (2)
ES (1)	ES2128846T3 (2)
FR (1)	FR06C0014I2 (2)
HU (1)	HU224028B1 (2)
IS (1)	IS2048B (2)
NO (1)	NO315968B1 (2)
NZ (1)	NZ304906A (2)
OA (1)	OA10515A (2)
PL (1)	PL183378B1 (2)
SK (1)	SK283883B6 (2)
TR (1)	TR199701048T1 (2)
UA (1)	UA41446C2 (2)
WO (1)	WO1996030010A2 (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP646A (en) *	1995-03-27	1998-04-27	Sanofi Synthelabo	Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
EP0799616A1 (en) *	1996-04-01	1997-10-08	Takeda Chemical Industries, Ltd.	Oral composition comprising a fumagillol derivative
ES2286998T3 (es)	1999-02-26	2007-12-16	Sanofi-Aventis	Formulacion estable que contiene fumagillina.
JP3265394B1 (ja) *	2001-03-14	2002-03-11	泰三矢野	アクリル系樹脂手袋
DE10341887A1 (de) *	2003-09-09	2005-03-31	Leopold Kostal Gmbh & Co. Kg	Elektrisches Schaltermodul
FR2886855B1 (fr) *	2005-06-08	2009-07-17	Agronomique Inst Nat Rech	Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CN101990441A (zh) *	2007-11-28	2011-03-23	默萨那治疗学股份有限公司	生物相容的生物可降解的烟曲霉素类似物轭合物
US8865746B2 (en) *	2008-07-18	2014-10-21	Zafgen, Inc.	Methods of treating an overweight or obese subject
WO2010065877A2 (en)	2008-12-04	2010-06-10	Zafgen Corporation	Methods of treating an overweight or obese subject
WO2010065883A2 (en)	2008-12-04	2010-06-10	Zafgen Corporation	Method of treating an overweight or obese subject
EP2486004B1 (en)	2009-10-09	2017-05-03	Zafgen, Inc.	Sulphone compounds for use in the treatment of obesity
AU2011204267B2 (en)	2010-01-08	2015-12-03	Zafgen Corporation	Fumagillol type compounds and methods of making and using same
US8815309B2 (en)	2010-01-08	2014-08-26	Zafgen, Inc.	Methods of treating a subject with benign prostate hyperplasia
WO2011127304A2 (en)	2010-04-07	2011-10-13	Zafgen Corporation	Methods of treating an overweight subject
CN103249735B (zh)	2010-07-22	2016-04-06	扎夫根股份有限公司	三环化合物及其制备和使用方法
PH12013500934A1 (en)	2010-11-09	2022-10-24	Zafgen Inc	Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012075020A1 (en)	2010-11-29	2012-06-07	Zafgen Corporation	Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
KR20140006888A (ko)	2011-01-26	2014-01-16	자프겐 인크.	테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
CN103534244B (zh)	2011-03-08	2016-10-12	扎夫根股份有限公司	氧杂螺[2.5]辛烷衍生物及类似物
BR112013028666A2 (pt)	2011-05-06	2017-08-08	Zafgen Inc	compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
CA2835261C (en)	2011-05-06	2019-06-04	Zafgen, Inc.	Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en)	2011-05-06	2016-01-21	Zafgen Inc.	Tricyclic sulfonamide compounds and methods of making and using same
EP2763671A2 (en)	2011-10-03	2014-08-13	Zafgen, Inc.	Methods of treating age related disorders
JP2015509102A (ja)	2012-01-18	2015-03-26	ザフゲン，インコーポレイテッド	三環式スルホン化合物並びにその作製および使用方法
MX2014008706A (es)	2012-01-18	2015-03-05	Zafgen Inc	Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
US9260419B2 (en)	2012-05-07	2016-02-16	Zafgen, Inc.	Polymorphic salt of a metap-2 inhibitor and methods of making and using same
AU2013259617A1 (en)	2012-05-08	2014-11-27	Zafgen, Inc.	Treating hypothalamic obesity with MetAP2 inhibitors
MX356755B (es)	2012-05-09	2018-06-11	Zafgen Inc	Compuestos de tipo fumagilol y metodos para su elaboración y uso.
BR112015010223A2 (pt)	2012-11-05	2017-07-11	Zafgen Inc	compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
NZ707773A (en)	2012-11-05	2019-05-31	Zafgen Inc	Methods of treating liver diseases
JP2015536981A (ja)	2012-11-05	2015-12-24	ザフゲン，インコーポレイテッド	三環式化合物ならびにその製造および使用方法
CN105228610A (zh)	2013-03-14	2016-01-06	扎夫根股份有限公司	治疗肾疾病和其它病症的方法
CN106432255A (zh)	2015-08-11	2017-02-22	扎夫根公司	烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es)	2015-08-11	2017-10-25	Zafgen Inc	Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) *	2015-10-15	2019-10-11	中国科学院微生物研究所	一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) *	2016-02-25	2018-06-26	中国农业科学院蜜蜂研究所	一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2791530A (en) *	1953-08-31	1957-05-07	Abbott Lab	Stabilized fumagillin compositions
JPH0629278B2 (ja) *	1985-06-26	1994-04-20	藤沢薬品工業株式会社	オキサスピロオクタン化合物
US5135920A (en) *	1988-11-16	1992-08-04	Takeda Chemical Industries, Ltd.	Angiostatic agents
WO1992002240A2 (en) *	1990-07-27	1992-02-20	Repligen Corporation	Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en)	1993-03-01	1994-07-12	Emory University	Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
AP646A (en) *	1995-03-27	1998-04-27	Sanofi Synthelabo	Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
EP0799616A1 (en) *	1996-04-01	1997-10-08	Takeda Chemical Industries, Ltd.	Oral composition comprising a fumagillol derivative
CA2210600A1 (en) *	1996-07-17	1998-01-17	Takashi Houkan	Inhibitor of tumor metastasis or recurrence
AU3968597A (en) *	1996-08-02	1998-02-25	Children's Medical Center Corporation	Method of regulating the female reproductive system through angiogenesis inhibitors

1996
- 1996-03-26 AP APAP/P/1997/001092A patent/AP646A/en active
- 1996-03-26 WO PCT/FR1996/000448 patent/WO1996030010A2/fr not_active Ceased
- 1996-03-26 JP JP52900196A patent/JP3260378B2/ja not_active Expired - Lifetime
- 1996-03-26 EP EP96909200A patent/EP0817626B1/fr not_active Expired - Lifetime
- 1996-03-26 CA CA002216623A patent/CA2216623C/en not_active Expired - Lifetime
- 1996-03-26 ES ES96909200T patent/ES2128846T3/es not_active Expired - Lifetime
- 1996-03-26 EA EA199700267A patent/EA000150B1/ru not_active IP Right Cessation
- 1996-03-26 TR TR97/01048T patent/TR199701048T1/xx unknown
- 1996-03-26 DE DE69600879T patent/DE69600879T2/de not_active Expired - Lifetime
- 1996-03-26 CN CN96192923A patent/CN1072485C/zh not_active Expired - Lifetime
- 1996-03-26 PL PL96322470A patent/PL183378B1/pl unknown
- 1996-03-26 UA UA97094765A patent/UA41446C2/uk unknown
- 1996-03-26 SK SK1307-97A patent/SK283883B6/sk not_active IP Right Cessation
- 1996-03-26 HU HU9801220A patent/HU224028B1/hu active IP Right Grant
- 1996-03-26 US US08/913,360 patent/US5900431A/en not_active Expired - Lifetime
- 1996-03-26 AU AU52786/96A patent/AU706161B2/en not_active Expired
- 1996-03-26 KR KR1019970706675A patent/KR100286920B1/ko not_active Expired - Lifetime
- 1996-03-26 CZ CZ19973049A patent/CZ286821B6/cs not_active IP Right Cessation
- 1996-03-26 NZ NZ304906A patent/NZ304906A/xx not_active IP Right Cessation
- 1996-03-26 DK DK96909200T patent/DK0817626T3/da active
- 1996-03-26 AT AT96909200T patent/ATE172641T1/de active
1997
- 1997-09-11 IS IS4557A patent/IS2048B/is unknown
- 1997-09-26 OA OA70088A patent/OA10515A/fr unknown
- 1997-09-26 NO NO19974466A patent/NO315968B1/no not_active IP Right Cessation
2006
- 2006-04-04 FR FR06C0014C patent/FR06C0014I2/fr active Active

Also Published As

Publication number	Publication date
DE69600879D1 (de)	1998-12-03
HUP9801220A3 (en)	2001-10-29
NO974466L (no)	1997-09-26
SK283883B6 (sk)	2004-04-06
NO974466D0 (no)	1997-09-26
HUP9801220A2 (hu)	1999-09-28
HU224028B1 (hu)	2005-05-30
KR19980703271A (ko)	1998-10-15
WO1996030010A2 (fr)	1996-10-03
ATE172641T1 (de)	1998-11-15
CZ286821B6 (en)	2000-07-12
PL322470A1 (en)	1998-02-02
CZ304997A3 (en)	1997-12-17
NO315968B1 (no)	2003-11-24
JPH11506421A (ja)	1999-06-08
AU706161B2 (en)	1999-06-10
EP0817626A2 (fr)	1998-01-14
MX9707150A (es)	1998-07-31
CN1072485C (zh)	2001-10-10
UA41446C2 (uk)	2001-09-17
CN1179715A (zh)	1998-04-22
EA000150B1 (ru)	1998-10-29
AU5278696A (en)	1996-10-16
DK0817626T3 (da)	1999-07-12
EA199700267A1 (ru)	1998-04-30
CA2216623A1 (en)	1996-10-03
TR199701048T1 (xx)	1998-01-21
JP3260378B2 (ja)	2002-02-25
WO1996030010A3 (fr)	1996-11-28
KR100286920B1 (ko)	2001-04-16
IS4557A (is)	1997-09-11
FR06C0014I1 (2)	2006-11-17
DE69600879T2 (de)	1999-06-02
EP0817626B1 (fr)	1998-10-28
IS2048B (is)	2005-09-15
NZ304906A (en)	1999-06-29
US5900431A (en)	1999-05-04
SK130797A3 (en)	1998-03-04
OA10515A (fr)	2002-04-24
AP9701092A0 (en)	1997-10-31
ES2128846T3 (es)	1999-05-16
FR06C0014I2 (2)	2006-12-29
AP646A (en)	1998-04-27
PL183378B1 (pl)	2002-06-28

Legal Events

Date	Code	Title	Description
2000-02-16	EEER	Examination request
2016-05-31	MKEX	Expiry	Effective date: 20160329

Publication	Publication Date	Title
US5900431A (en)	1999-05-04	Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
JPH0621079B2 (ja)	1994-03-23	下痢止め組成物及びその用途
CA1243605A (en)	1988-10-25	Antidiarrheal compositions and use thereof
KR20000016266A (ko)	2000-03-25	비수용성 결장 하제 조성물_
US5348744A (en)	1994-09-20	Antidiarrheal compositions containing loperamide hydrochloride and a saccharide
US5837256A (en)	1998-11-17	Method for treatment of Lupus nephritis
EP0786993A1 (en)	1997-08-06	Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
EP0190851B1 (en)	1990-01-03	Improved antiinflammatory composition
US4895851A (en)	1990-01-23	Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
MXPA97007150A (en)	1998-11-09	Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
CA2255640A1 (en)	1997-11-27	Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
US20230144875A1 (en)	2023-05-11	Highly purified eicosapentaenoic acid, as free fatty acid for treatment of coronaviruses and specifically novel coronavirus-19 (covid-19)
EP0555302A1 (en)	1993-08-18	Method of treating demyelinating disease
US7485642B2 (en)	2009-02-03	Method for treating septic shock
US20070093519A1 (en)	2007-04-26	Anti-emetic uses of cannabinoid analogs
JPS63145233A (ja)	1988-06-17	白内障治療剤
JPH0132804B2 (2)	1989-07-10
JPH04266822A (ja)	1992-09-22	システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
EP0118968A1 (en)	1984-09-19	Use of avilamycin to control swine dysentery
WO2020242410A1 (en)	2020-12-03	Pharmaceutical compositions comprising ursodeoxycholic acid as active substance
FR2566664A1 (fr)	1986-01-03	Composition utile au traitement de la diarrhee contenant du dextromethorphan
WO1996011679A1 (en)	1996-04-25	Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders